University of Maryland, Baltimore | Date: 2017-02-15
The present invention provides a method for imaging microtentacles on isolated, living, non-adherent primary tumor cells from a cancer subject comprising: i) obtaining one or more living, non-adherent primary tumor cells that has been isolated from a solid tumor from the subject; and ii) imaging the one or more living, non-adherent primary tumor cells and detecting the microtentacles.
University of Maryland, Baltimore and Tel Aviv University | Date: 2017-03-29
The beta 2 subunit of mouse hemoglobin (HBB2) has been identified as soluble factor from mouse lungs that exhibits cytostatic/cytotoxic activity against neuroblastoma lung micrometastases. The beta subunit of human hemoglobin (HBB) has been found to have similar activity. Methods of using these proteins and fragments thereof in the treatment of cancer and inhibition of metastasis are provided, along with methods of screening a subject for micrometastases by detecting HBB in a biological sample.
University of Maryland, Baltimore | Date: 2017-02-08
Embodiments of the disclosure include methods and compositions related to treatment of one or more medical conditions with one or more negative modulators of GABAA receptors. In specific embodiments, depression and/or suicidality is treated or ameliorated or prevented with one or more negative modulators of GABAA receptors, such as a partial inverse agonist of a GABAA receptor comprising an alpha5 subunit.
University of Maryland, Baltimore and The University Of Texas System | Date: 2017-03-15
The present invention provides a method for predicting whether a human patient 65 years of age or older is at increased risk for developing heart failure, comprising obtaining the results of an assay that measures levels of NT-proBNP and/or cardiac troponin T in a specimen from the patient wherein an increased NT- proBNP and/or cardiac troponin T level compared to levels in a control indicate an increased risk for developing heart failure.
University of Maryland, Baltimore | Date: 2017-05-31
The present invention provides protein-repellent dental materials that can be widely applied in a variety of dental applications. The protein-repellent dental materials of the invention include dental primers, dental adhesives, dental resins, dental composites, dental bonding systems and the like, as well as dental cements, dental sealants, dental bases and dental liners, each of which is protein-repellent and each of which comprises a protein-repellent agent. In certain aspects, the protein-repellent agent is 2-methacryloyloxyethyl phosphorylcholine (MPC).
University of Maryland, Baltimore and University of Maryland Baltimore County | Date: 2017-02-08
The present invention discloses methods and systems to control magnetic fields and magnetic field induced currents, and more particularly to provide stimulations within a patients body, such as deep brain stimulation, in a non-invasive manner and with greater focus and control than has been afforded by prior known methods and systems. In accordance with certain aspects of an embodiment, an array of magnetic coils is provided and positionable about a portion of a patients body. During operation, at least some of the magnetic coils function as DC coil pairs configured to generate a DC magnetic field, while at least some of the other magnetic coils function as transient magnetic field generators to generate an induced current within a portion of the patients body, such as in a region of the patients brain. The system is configured such that the DC magnetic fields may be used to manipulate the transient magnetic fields, in turn allowing significantly improved control and focus of the induced current within a specifically desired volume of interest within a patients body.
University of Maryland, Baltimore and University of Maryland College Park | Date: 2017-05-17
The present invention provides a method of treating a condition affecting a tooth or periodontium in a subject, comprising administering to the subjects tooth or periodontium a composition comprising biocompatible magnetic, magnetizable, or magnetically responsive agents; and applying an external magnetic field, wherein the magnetic, magnetizable, or magnetically responsive agents migrate to a desired location in response to the externally applied magnetic field, thereby treating a condition affecting the tooth or periodontium in the subject.
University of Maryland, Baltimore | Date: 2017-01-04
The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NC_(Ca-ATP )channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NC_(Ca-ATP )channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the NC_(Ca-ATP )channel, including SUR1 antagonists, are useful in the prevention, diminution, and treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury. Agonists of the NC_(Ca-ATP )channel may be are useful in the treatment neural tissue where damage or destruction of the tissue, such as a gliotic capsule, is desired.
University of Maryland, Baltimore | Date: 2017-01-06
The present invention provides dental bonding agents and dental bonding systems comprising the dental bonding agents. The dental bonding agents of the invention are characterized by having antibacterial properties, and in some aspects of the invention, remineralizing properties.
University of Maryland, Baltimore | Date: 2017-09-20
The present invention discloses a self-sealing cannula and methods of its use. The self-sealing cannula can be minimally invasively placed into the heart for drawing and/or returning blood with a self-sealing function at the interface of the blood access site. The disclosed cannula can be implemented as a single lumen cannula or a double lumen cannula, which can be used with ventricular assist devices for heart support or pump-oxygenators for ECMO and respiratory support. Through a self-sealing mechanism fixed on the ventricular wall or atrial wall, a cannula body is attached to the self-sealing fixture and blood is drawn into the lumen via an external pump and returned to the circulation system through a separate cannula. In the case of the double lumen cannula embodiment, the blood will be drawn into the drainage lumen of the double lumen cannula and returned through an infusion lumen at the desired location. The present invention achieves minimally invasive insertion without surgical sutures to the heart, and allows for optimal drainage of the blood from the heart. With use of the double lumen cannula, it prevents need for multiple cannulation sites, and greatly reduces the blood recirculation. Removal of the cannula is simplified without need for suturing or insertion of a plugging member.